SCHEMBL6357950

SCHEMBL6357950

CCOC(=O)N(CC(=O)c1ccccc1)C(C(N)=O)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
POLB P06746 2/20 0.48
LMNA P02545 1/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
NPC1 O15118 2/20 0.46
TRPM8 Q7Z2W7 2/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 3/20 0.37
AGTR1 P30556 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6354396 0.90 ALDH1A1 (0.57) ALDH1A1POLBLMNAHSD17B10L3MBTL1
SCHEMBL6356582 0.89 SLC6A2 (0.43) ALDH1A1POLBLMNAHSD17B10L3MBTL1
SCHEMBL6350601 0.87 KMT2A (0.42) ALDH1A1POLBLMNAL3MBTL1KMT2A
SCHEMBL6347856 0.82 ALDH1A1 (0.43) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL6359179 0.82 TRPM8 (0.47) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL6350864 0.82 TRPM8 (0.47) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL6354208 0.82 ALDH1A1 (0.43) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL6347733 0.82 ALDH1A1 (0.43) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL6359360 0.82 KMT2A (0.38) ALDH1A1POLBLMNAL3MBTL1KMT2A
SCHEMBL6350685 0.82 KMT2A (0.38) ALDH1A1POLBLMNAL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 ALDH1A1 420/4885POLB 3917/4885LMNA 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.